7MW 3711
Alternative Names: 7MW-3711Latest Information Update: 12 Sep 2025
At a glance
- Originator Mabwell (Shanghai) Bioscience
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Small cell lung cancer; Solid tumours
Most Recent Events
- 12 Sep 2025 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease) in China (IV) (Mabwell (Shanghai) Bioscience pipeline, September 2025)
- 30 May 2025 Efficacy and adverse events data from a phase I/II trial in Solid tumors presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 30 May 2025 Efficacy and adverse events data from a phase I/II trial in Solid tumors presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)